Skip to content
Open access

Disrupting Treg lineage stability elicits RORgT-mediated plasticity and enhances anti-tumor immunity.

Jul 2026 · Cell Death and Disease · 0 citations
Medicine

TL;DR

These findings highlight Hh/Gli2 signaling in Tregs as a mechanistic regulator of immunogenicity in the TME and a potential therapeutic target to prime tumors for enhanced responsiveness for adjuvant treatments.

Abstract

The imbalance of pro-inflammatory and immunosuppressive constituents in the tumor microenvironment (TME) significantly dictates cancer progression, immune invasion, and treatment response. Immunosuppressive regulatory T cells (Tregs) are associated with decreased disease-free survival due to their ability to suppress anti-tumor immunity. Notably, in response to environmental cues, Tregs display functional and phenotypic plasticity with inflammatory helper T cell subsets. Given their predominant role in sustaining immune suppression, it is remarkable that multiple developmental pathways converge to regulate Treg development and function. In this study, we designed, validated, and employed a novel genetically modified mouse model to conditionally ablate the Hedgehog (Hh) gene, Gli2, specifically in Tregs. Ablation of Gli2 activity in Tregs significantly reduced tumor burden, impaired Treg suppressive function, and shifted the transcriptional balance of Foxo3 and Rorγt, transcription factors essential for Tregs and Th17 cells. Spatial mapping highlighted that Gli2 ablation in Tregs enhances the immunogenicity of the tumor and promotes a pro-inflammatory milieu of the TME. This was underscored by a higher tumor immune signature score and enhanced infiltration of cytotoxic CD8+ T cells into the tumor. These findings highlight Hh/Gli2 signaling in Tregs as a mechanistic regulator of immunogenicity in the TME and a potential therapeutic target to prime tumors for enhanced responsiveness for adjuvant treatments.

Read PDF

Similar papers

Open access Jul 2026

Targeting genome organizer Satb1 in regulatory T cells safely and potently enhances cancer immunity 2309560

Deletion of Satb1 specifically in Tregs impaired the function of Satb1+ pro-tumorigenic Tregs, leading to enhanced CD8+ T cell antitumor immune responses, and complete tumor eradication without any systemic autoimmune conditions.

Ephraim A. Ansa-Addo, Parviz Azimnasab-sorkhabi, Musab Bouhajra et al. · 0 citations
Review Open access Aug 2026

Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities

Targeting the mechanisms regulating Treg recruitment, stability, or suppressive function may represent a promising strategy to enhance the efficacy of immunotherapies including Bacillus Calmette–Guérin therapy.

Yusuke Fukiage, Nodoka Okubo, M. Taga et al. · 0 citations
Open access Aug 2026

Fragility and Plasticity of CCR8+Tregs: Providing New Directions for Cancer Treatment

Regulatory T cells (Tregs) are crucial for maintaining immune homeostasis. However, in the tumor microenvironment, tumor cells induce Tregs to exert immunosuppressive effects, leading to the failure of anti-tumor immunity. Traditional Treg clearance strategies, due to their lack of selectivity, damage peripheral normal...

Yu-Hao He · 0 citations
Open access Aug 2026

An integrated SOX4-driven transcriptional and metabolic program governs tumor-infiltrating regulatory T cells in ovarian cancer

Background Regulatory T cells (Tregs) suppress antitumor immunity in ovarian cancer (OC) and are promising targets for immunotherapy. However, the heterogeneity and regulatory mechanisms of tumor-infiltrating Tregs (TI-Tregs) remain poorly defined. Here, we aim to delineate TI-Treg programs to identify potential therap...

Lei Wu, Ziqi Tao, Yue-Lu Zhang et al. · 0 citations
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

Despite the remarkable progress in cancer treatment, drug resistance and immune escape still severely limit clinical efficacy, largely due to tumor-induced immunosuppression. The main driver of this suppressive environment is myeloid-derived suppressor cells (MDSCs). Tumor-derived cytokines and chemokines can induce th...

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Review Aug 2026

Myeloid-derived suppressor cells in the tumor microenvironment: cellular crosstalk, immunosuppressive effects, and therapeutic targets.

Together, current evidence indicates that MDSCs represent context-dependent therapeutic nodes, while functional reprogramming, spatially resolved profiling, and patient stratification may improve immunotherapy outcomes.

Lisichen Zhu, Hui Liu, Sihan Zhang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.